These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 8002862)
1. Profound suppression of plasma alanine aminotransferase activity in children taking vigabatrin. Williams A; Goldsmith R; Coakley J Aust N Z J Med; 1994 Feb; 24(1):65. PubMed ID: 8002862 [No Abstract] [Full Text] [Related]
2. Vigabatrin causes profound reduction in serum alanine transaminase activity. Ryan MF; Samy A; Young J Ann Clin Biochem; 1996 May; 33 ( Pt 3)():257-8. PubMed ID: 8791991 [No Abstract] [Full Text] [Related]
3. Reduction of plasma alanine aminotransferase during vigabatrin treatment. Foletti GB; Delisle MC; Bachmann C Epilepsia; 1995 Aug; 36(8):804-9. PubMed ID: 7635099 [TBL] [Abstract][Full Text] [Related]
4. Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin. Williams A; Sekaninova S; Coakley J J Paediatr Child Health; 1998 Aug; 34(4):395-7. PubMed ID: 9727187 [TBL] [Abstract][Full Text] [Related]
7. Aminoaciduria resulting from vigabatrin administration in children with epilepsy. Lahat E; Ben-Zeev B; Zlotnik J; Sela BA Pediatr Neurol; 1999 Jul; 21(1):460-3. PubMed ID: 10428431 [TBL] [Abstract][Full Text] [Related]
8. Cognitive effects of vigabatrin: a review. Monaco F Neurology; 1996 Jul; 47(1 Suppl 1):S6-11. PubMed ID: 8677033 [TBL] [Abstract][Full Text] [Related]
9. In vitro effects of the novel anti-epileptic agent vigabatrin on alanine aminotransferase and aspartate aminotransferase activities in rat serum. Okumura H; Omote M; Takeshita S Arzneimittelforschung; 1996 May; 46(5):459-62. PubMed ID: 8737626 [TBL] [Abstract][Full Text] [Related]
10. Fatal hepatotoxicity in a child treated with vigabatrin. Kellermann K; Soditt V; Rambeck B; Klinge O Acta Neurol Scand; 1996 May; 93(5):380-1. PubMed ID: 8800351 [No Abstract] [Full Text] [Related]
11. Visual field constriction in children treated with vigabatrin. Vanhatalo S; Pääkkönen L; Nousiainen I Neurology; 1999 May; 52(8):1713-4. PubMed ID: 10331710 [No Abstract] [Full Text] [Related]
12. Vigabatrin. Guberman A Can J Neurol Sci; 1996 Nov; 23(4 Suppl 2):S13-7. PubMed ID: 8951215 [TBL] [Abstract][Full Text] [Related]
13. [Vigabatrin in the treatment of pediatric epileptic syndrome]. Lahat E Harefuah; 1995 Mar; 128(5):306-8. PubMed ID: 7744355 [No Abstract] [Full Text] [Related]
14. Vigabatrin in childhood epilepsy: a 5-year follow-up study. Uldall P; Alving J; Gram L; Høgenhaven H Neuropediatrics; 1995 Oct; 26(5):253-6. PubMed ID: 8552215 [TBL] [Abstract][Full Text] [Related]
15. Immunologic aspects of vigabatrin treatment in epileptic children. Pacifici R; Zuccaro P; Iannetti P; Raucci U; Imperato C Epilepsia; 1995 Apr; 36(4):423-6. PubMed ID: 7607123 [TBL] [Abstract][Full Text] [Related]
16. [Vigabatrin symposium within the congress "Epilepsy Europe", 3 September 1992, Glasgow]. Nervenarzt; 1992 Dec; 63(12 Suppl):1-12. PubMed ID: 7477593 [No Abstract] [Full Text] [Related]
17. The new antiepileptic drugs. Macleod S; Appleton RE Arch Dis Child Educ Pract Ed; 2007 Dec; 92(6):182-8. PubMed ID: 18032714 [No Abstract] [Full Text] [Related]
19. Evidence for both in vivo and in vitro interaction between vigabatrin and alanine transaminase. Richens A; McEwan JR; Deybach JC; Mumford JP Br J Clin Pharmacol; 1997 Feb; 43(2):163-8. PubMed ID: 9131948 [TBL] [Abstract][Full Text] [Related]
20. [New drugs in the treatment of childhood epilepsy: vigabatrin (study of 61 subjects)]. Raucci U; Spalice A; Basile LA; Guardalà C; Nasta L; Terenzi S; Iannetti P Pediatr Med Chir; 1994; 16(6):575-8. PubMed ID: 7708543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]